Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4335813 | 0.93 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DNAMPT | |
| SCHEMBL4329117 | 0.89 | ROCK2 (0.44) | PDE4APDE4BPDE4CPDE4DPKM | |
| SCHEMBL4323530 | 0.83 | NPC1 (0.55) | SMN1; SMN2NPC1RAB9ATRPV1 | |
| SCHEMBL4326402 | 0.82 | NPC1 (0.51) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL4321929 | 0.82 | NAMPT (0.44) | NAMPTADORA2AADORA1SMN1; SMN2NPC1 | |
| SCHEMBL4331265 | 0.81 | CHRNB2 (0.41) | PDE4APDE4BPDE4CPDE4DNAMPT | |
| SCHEMBL4322905 | 0.80 | ATR (0.47) | PDE4APDE4BPDE4CPDE4DNAMPT | |
| SCHEMBL4332310 | 0.79 | ATR (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL4334597 | 0.79 | PABPC1 (0.48) | PDE4APDE4BPDE4CPDE4DNAMPT | |
| SCHEMBL4320261 | 0.78 | ATR (0.51) | PDE4APDE4BPDE4CPDE4DPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | PDE4A 522/4885PDE4B 534/4885PDE4C 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.